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Wecompared transcriptomes of terminally differenti-
atedmouse 3T3-L1 and human adipocytes to identify
cell-specific differences. Gene expression and high
content analysis (HCA) data identified the androgen
receptor (AR) as both expressed and functional,
exclusively during early human adipocyte differen-
tiation. The AR agonist dihydrotestosterone (DHT)
inhibited human adipocyte maturation by downregu-
lation of adipocytemarker genes, but not in 3T3-L1. It
is interesting that AR induction corresponded with
dexamethasone activation of the glucocorticoid
receptor (GR); however, when exposed to the differ-
entiation cocktail required for adipocyte maturation,
AR adopted an antagonist conformation and was
transcriptionally repressed. To further explore effec-
tors within the cocktail, we applied an image-based
support vector machine (SVM) classification scheme
to show that adipocyte differentiation components
inhibit AR action. The results demonstrate human
adipocyte differentiation, via GR activation, upregu-
lates AR but also inhibits AR transcriptional activity.
INTRODUCTION
White adipose tissue is a central metabolic organ that regulates
energy balance by storing and mobilizing lipids. In lean individ-
uals, adipocytes maintain a dynamic equilibrium between tri-
glyceride storage and lipolysis. On the other hand, obese
subjects have enlarged adipocytes resulting from high caloric
intake and increased triglyceride storage in larger lipid droplets.
As the obesity epidemic continues to spread, it is likely that
a variety of therapeutic intervention strategies will be evaluated,
including the targeting of metabolic pathways directly involved
in fat synthesis and storage (Guilherme et al., 2008). Thus, the
identification of genes associated with human adipocyte
differentiation is key to understanding fat deposition and the
pathogenesis of obesity.1126 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201There is now significant evidence suggesting androgens are
important regulators of energy balance, fat deposition, and
body composition in males and females (Blouin et al., 2009b),
while also influencing other endocrine targets including bone
and skeletal muscle (Zitzmann, 2009). It is well established that
men experience an increase in body mass index as a conse-
quence of hypogonadism and aging, conditions associated
with a decreased level of circulating testosterone (Gould et al.,
2007). In women, the association between obesity and andro-
gens is more enigmatic and poorly characterized. Although
female androgen receptor (AR) deficiency has not been well
studied, women with complete androgen insensitivity syndrome
have increased fat mass (Dati et al., 2009). On the other hand,
hyperandrogenemia has been known to provoke insulin resis-
tance, independent of obesity (Coviello et al., 2006) through
systemic oxidative stress, including disruption of b-cell function
(Liu et al., 2010). However, levels of AR do not predict fat distri-
bution or negatively correlate with BMI inmen andwomen (Wake
et al., 2007), suggesting that AR activity per se might be differen-
tially regulated in obese versus lean states.
Androgens influence gene transcription through activation
of AR, a member of the nuclear receptor (NR) superfamily of
transcription factors (Chang et al., 1988; Lubahn et al., 1988).
Upon ligand binding, conformational change, and homodimeri-
zation, AR can regulate gene transcription by binding to specific
DNA motifs (Schoenmakers et al., 2000) that constitute con-
sensus hormone response elements (HREs) in AR target genes.
Consensus HREs are also recognized by the glucocorticoid
receptor (GR), allowing extensive crosstalk between receptors
(Lieberman et al., 1993; Nordeen et al., 1990; Roche et al.,
1992) and shared target genes, including the immunophilin
FKBP5 (Magee et al., 2006). Indeed, recent genome-wide anal-
yses have shown that AR and GR binding sites in nonadipocyte
cells are enriched in pathways associated with lipid and fatty
acid metabolism (Bolton et al., 2007; Massie et al., 2011; Reddy
et al., 2009). In 3t3-L1 cells (Yu et al., 2010), primary GR target
genes are involved in fatty acid transport (FABP4; Hotamisligil
et al., 1996), energy storage (CIDEC; Nishino et al., 2008), and
those that are adipocyte specific (PPARg2; Tontonoz et al.,
1994). Genome-wide analysis of AR binding in adipocytes has
yet to be performed.2 Elsevier Ltd All rights reserved
Figure 1. Microarray Analysis Identifies Unique Profiles Associated
with Mouse—3T3-L1—and Human Adipocyte Differentiation Models
(A) Comparison of the human expression data to a compatible data set
generated in mouse 3T3-L1 found 3,496 and 1,467 genes exclusive to mouse
and human microarrays, respectively, with an 817-gene overlap. See also
Supplemental Excel File S1.
(B) Of the 1,467 genes regulated in the human class, human AR was detected
and validated by qPCR (*p < 0.05 vs. Day 0).
(C) Expression of AR in mouse tissues and cell lines. Total mRNA was isolated,
and AR transcript levels were compared between epididymal fat (EF),
subcutaneous fat (SF), mesenteric fat (MF), peritoneal fat (PF) depots (n = 3
mice), and terminally differentiated 3T3-L1 (9 d).
See also Figure S1.
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Chemistry & Biology 19, 1126–114Overall, cell-based studies in human preadipocytes (Blouin
et al., 2009a, 2010; Gupta et al., 2008) and 3T3-L1 (Singh
et al., 2006) have shown that androgens suppress lipid accumu-
lation during late-stage, terminal endpoints. Here, we have
analyzed the transcriptomes of terminally differentiated mouse
3T3-L1 and human adipocytes to identify species-specific genes
and pathways involved in the adipogenic process. When we
analyzed mRNAs changing during adipogenesis in vitro, we
identified an increase in AR mRNA specifically in human adipo-
cytes, while it was undetectable in differentiating 3T3-L1 cells.
Because the regulation of AR and a dominant functional role
remains largely undefined, we complemented our transcriptomic
discovery with image-based and chemical biology approaches
to identify and classify dominant mechanisms of AR regulation
in adipocytes.
RESULTS
Identification of Genes Unique to Human Adipocyte
Differentiation
To identify genes associated with human adipocyte differ-
entiation in vitro, we used Illumina whole genome arrays to
measure gene expression in subcutaneous primary human
adipocytes treated for up to 14 days with rosiglitazone, 3-isobu-
tyl-1-methylxanthine (IBMX), dexamethasone, and insulin (MIX).
An analysis of variance (ANOVA) of gene expression revealed
2674 differentially regulated array features with many of the
standard genes associated with adipocyte differentiation upre-
gulated (Figure S1 available online). Next, we compared gene
expression data between terminally differentiated mouse 3T3-
L1 adipocytes (Schuppet al., 2009) and humanadipocytes differ-
entiated for 14 days. As expected, overlapping probe sets (817;
Figure 1A) comprised transcription factors critical for adipocyte
differentiation, including PPARg (Rosen et al., 1999) and CEBPa
(Rosen et al., 2002), and genes classically associated with
cholesterol/fat/lipid metabolism programs, including ADIPOQ,
FABP4, ABCA1, CD36, and FASN, among others (Supplemental
Excel File S1). However, we also detected 3,496 and 1,496 genes
uniquely expressed in 3T3-L1 (Supplemental Excel File S1) and
human (Supplemental Excel File S1) adipocytes, respectively.
Of the genes detected that were changing in the human arrays,
ARmRNA was upregulated 3.5-fold between Day 0 and Day 14.
We validated the induction of AR mRNA using quantitative real-
time PCR (qPCR) and measured a 3.35-fold induction as early
as Day 1, and a 12.3-fold increase over the 14-day differentiation
period (Figure 1B). For comparison, wemeasuredAR expression
in primary mouse adipose tissue. We found AR mRNA was
expressed in epididymal fat (EF), subcutaneous fat (SF), mesen-
teric fat (MF), and peritoneal fat (PF) at 910, 376, 302, and 1,484
times the level, respectively, of AR expression in mature 3T3-L1
adipocytes (Figure 1C). Our initial findings indicated AR was not
highly expressed in 3T3-L1 adipocytes.
DHT Inhibits Human Adipocyte Differentiation
Since AR mRNA was detected as a significantly expressed and
induced gene in human adipocytes, we hypothesized that
this differentiation program would be sensitive to androgen
(dihydrotestosterone [DHT]) treatment. To test this hypothesis,
we applied a set of previously customized image analysis tools1, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1127
Figure 2. Effect of an Androgen, Dihydrotestosterone, on Adipocyte Differentiation
(A) Human preadipocytes were induced to differentiate for 96 hr with rosiglitazone, insulin, dexamethasone, and IBMX (MIX) in the presence or absence of 10 nM
dihydrotestosterone (DHT). Cells were then stained with DAPI (DNA), CellMask Blue (CMBl, general protein dye), and LipidTOX (Lipid), followed by HTM. Scale
bar, 20 mm.
(B) Lysates were prepared from adipocytes differentiated for 4 days in the presence or absence of 10 nM DHT. Protein levels of AR and PPARgwere detected by
western blot.
(C) Human AR-FLAG (fAR) or vector control lentiviral particles were prepared and introduced into 3T3-L1 preadipocytes for 48 hr before chemical induction of
differentiation. Human AR expression was detected in both human adipocytes and 3T3L1 expressing fAR before and after 96 hr of differentiation.
(D) After cell differentiation in the presence or absence of 10 nM DHT for 96 hr, cells were processed for immunofluorescence to AR, stained for lipid and
DAPI/CMBl, and imaged. Scale bar, 20 mm.
(E and F) In (E) and (F), PPARg2 and FABP4 mRNA levels, respectively, were measured from 3T3L1 cells expressing vector (pcDH) or fAR differentiated in the
presence or absence of 10 nM DHT for 96 hr. (n = 2 independent experiments ± SEM, #p < 0.05 compared to no differentiation or *p < 0.05 compared to
differentiation without DHT).
(G) Lipid accumulation was quantified by HCA after lentiviral expression of human AR (n = average of four wells ± SEM) or androgen treatment in human
preadipocytes (n = five independent experiments ± SEM, *p < 0.05).
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cence-based measurements (e.g., high content analysis; HCA)
of NR and coregulator proteins, and, as a biomarker for differen-
tiation, levels of intracellular lipids (Hartig et al., 2011). As shown1128 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201in Figure 2A, MIX-induced adipocyte differentiation was reduced
by supplementation with 10 nM DHT at 96 hr as indicated
by reduced lipid accumulation. By western blotting, MIX supple-
mented with 10 nM DHT showed both decreased PPARg2 Elsevier Ltd All rights reserved
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Androgen Receptor Regulation in Human Adipocytesexpression and increased AR levels (Figure 2B). To further
validate the role of AR in adipocyte differentiation, we then
compared the effects of DHT on the differentiation of 3T3-L1
adipocytes when human AR was expressed by lentivirus. 3T3-
L1 cells were infected with either empty vector (pcDH) or virus
encoding human FLAG-AR (pcDH fAR). In response to vehicle
(dimethyl sulfoxide; DMSO) or MIX, AR expression in 3T3-L1
was approximately equal to levels found in human adipocytes
(Figure 2C). After 48 hr, cells were induced to differentiate with
standard 3T3-L1 adipogenic cocktail (dexamethasone, IBMX,
insulin) and ethyl alcohol (EtOH) (vehicle), or 10 nM DHT for
96 hr. DHT (10 nM) suppressed lipid accumulation (44% vs.
vehicle) only when AR was expressed by lentivirus and not in
the vector control (Figure 2D). The adipocyte-specfic genes
PPARg2 (54% vs. vehicle) (Figure 2E) and FABP4 (60% vs.
vehicle) (Figure 2F) were also significantly downregulated by
DHT only in 3T3-L1 cells expressing human AR. Furthermore,
we measured a 47% decrease in lipid accumulation in human
adipocytes, which compared well with the effect in 3T3-L1
when AR was expressed by lentivirus (Figure 2G). Our results
support previous observations demonstrating inhibition of
human adipocyte differentiation by AR agonists (Blouin et al.,
2009a, 2010; Gupta et al., 2008). Taken together, we speculated
the discrepancy in DHT-mediated inhibition of early adipocyte
differentiation between the two cell types is attributable to differ-
ences in their AR expression levels. Human adipocytes express
sufficient AR at a level where DHT can inhibit early adipogenesis,
while extremely low levels of AR in 3T3-L1 cells prohibit any
effect of DHT on lipid accumulation.
Human Adipocyte Differentiation Is Suppressed
by AR Activation
Wenext examined the effect of 10 nMDHT and 10 mMO-hydrox-
yflutamide (OHF), an AR antagonist, on expression of adipocyte-
specific mRNAs and nuclear levels of PPARg and AR in human
subcutaneous preadipocytes induced to differentiate by MIX.
Among positive cells, AR and PPARg exhibited a chiefly nuclear
signal (>75%) by immunofluorescence (Figure 3A), which was
independent of DHT and OHF. Using AR levels at 96 hr (90th
percentile) as a threshold to define AR-positive cells, we estab-
lished that DHT increased the number of AR positive cells by
3.3-fold compared to MIX (Figure 3B). Of note, the range of
expression for positive cells was less than one log between
minimum and maximum AR levels. As determined by Pearson’s
r calculation (N > 3,700 cells for all treatments), cells exhibiting
higher levels of AR as a result of androgen treatment did not
correspond with decreased nuclear PPARg (PrMIX/DHT = 0.105,
N = 4,765 cells). Indeed, no treatment induced a significant
correlation between nuclear AR and nuclear PPARg (Pr-MIX =
0.06; PrMIX = 0.09; PrMIX/OHF = 0.05), suggesting that an
upstream regulatory event might contribute to the regulation of
both receptors. Following 96 hr of treatment, differentiation of
human preadipocytes in the presence of DHT was associated
with reduced lipid accumulation (32%) (Figure 3C), dramati-
cally increased levels of AR protein (10-fold over vehicle)
(Figure 3D), and reduced levels of nuclear PPARg (20%)
(Figure 3E). AR protein stabilization by androgen appears to be
themain effect, as ARmRNA levels were only modestly changed
during differentiation in the presence of DHT (15% vs. no DHT)Chemistry & Biology 19, 1126–114(Figure 3F). Conversely, levels of adipocyte-associated (C/
EBPa, 79%; PPARg, 60%) and lipid storage (ADFP: 46%,
FASN: 70%) genes were all reduced under the same condi-
tions (Figure 3F). As a control, the mRNA level of the tran-
scriptional coactivator SRC-3 was not significantly affected by
differentiation in the presence of androgen (DHT) or antiandro-
gen (OHF). We suggest that AR activation by DHT leads to
an accumulation (stabilization) of nuclear AR (Furutani et al.,
2002), which reduces expression of PPARg mRNA and sub-
sequently slows adipocyte differentiation. Collectively, these
results extended the findings of Figure 2 and position the activity
of AR as a critical determinant of lipid storage in adipocytes.
GR Promotes AR Expression during Human
Adipocyte Differentiation
As a pioneer factor in preadipocytes, theGR is required to initiate
cell differentiation and activate transcription of proadipocyte
genes, including PPARg2 (Steger et al., 2010). Because recent
ChIP-Seq experiments in A549 cells found dexamethasone-
induced GR binding regions <10 kB upstream of the AR
promoter (Reddy et al., 2009) and AR was significantly upregu-
lated early (24 hr after differentiation; Figure 2A), we reasoned
GR might regulate AR expression. To test this hypothesis, GR
was downregulated by siRNA in preadipocytes. Subsequently,
cells were treated with MIX or vehicle (EtOH) for 96 hr. Using
immunofluorescence (Figure 4A) and HCA, we detected GR
knockdown (54% vs. scR siRNA) (Figure 4B) which corre-
sponded to both decreased lipid accumulation (35% vs. scR
siRNA) (Figure 4C) and reduced nuclear AR (52% compared
to scR siRNA). By qPCR (Figure 4E), GR siRNA inhibited AR
mRNA induction with significant downregulation of PPARg2,
adipogenic targets of PPARg and GR (FABP4, CIDEC), and
a canonical GR/AR target (FKBP5). The marked inhibition of
AR induction after GR siRNA suggested GR is required for early
upregulation of AR in adipocytes, in addition to the established
roles of GR as a primary regulator of early adipogenesis (Pantoja
et al., 2008; Steger et al., 2010).
Dexamethasone Is Required for AR Upregulation
in Human Adipocytes
To further understand the role of GR and dexamethasone in
driving AR upregulation, we examined the uncoupling of dexa-
methasone (dex) from the three other components (ixr: insulin,
IBMX, rosiglitazone) present in MIX. At the mRNA level (Fig-
ure 5A), dex supplementation was required for AR induction
(4.5-fold vs. EtOH) and maximal upregulation of PPARg2
(6.4-fold vs. EtOH). Target genes of PPARg2 and GR, FABP4,
CIDEC, and FKBP5, respectively, were each coordinately
and significantly upregulated when dex was added to ixr. As
observed in Figure 3F, the addition of 10 nM DHT to ixr+dex
treatments decreased the expression of PPARg2 (58%) and
genes associated with lipid transport (FABP4: 80%) and
storage (CIDEC: 60%). Upregulation of FKBP5 by dex supple-
mentation was unaffected by 10 nM DHT, indicating a dominant
effect of dex on target genes shared by both AR and GR.
In parallel experiments, we confirmed the qPCR findings
(Figure 5A) and dissected the regulation of AR by dex in
human adipocytes using HCA (Figure 5B). Addition of dex to
differentiation components (ixr) caused a decrease in GR1, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1129
Figure 3. AR Activation Suppresses Human Adipogenesis
(A) Images from human adipocytes differentiated for 96 hr with the indicated ligand treatments, immunolabeled with antibodies to PPARg (gray scale) or AR (red),
and stained with LipidTOX (Lipid, green), and DAPI. On the leftmost panels, masks (red) generated by image analysis algorithmswere overlaid onto the DAPI (gray
scale) images to indicate cell and nucleus borders. Scale bar, 50 mm.
(B) Percent AR-positive cells was defined by measuring the 90th percentile expression level for +MIX and applying that threshold to single cell distributions of AR
for the other three treatments. The effect of androgens on the rate of lipid accumulation, nuclear PPARg, and nuclear AR was determined by differentiation of
human preadipocytes for the indicated time points in the presence of DHT, vehicle (EtOH), or OHF.
(C–F) HCA was used to quantify the induction of (C) lipid accumulation, (D) AR, and (E) PPARg. In parallel, relative mRNA was determined for (F) AR, C/EBPa,
PPARg, ADFP, FASN, and SRC-3.
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and proteasome-dependent downregulation mechanism (Wal-
lace and Cidlowski, 2001). While the mRNA data indicated that
dex was required to upregulate ARmRNA (Figure 5A), DHT addi-
tion to any treatment was sufficient to increase AR protein levels
with a maximum observed induction of 8.9-fold (ixr+dex+DHT)
providing further evidence of androgen-mediated AR stabiliza-
tion in adipocytes. Collectively, these data show lipid accumula-
tion requires dex, and it is inhibited by supplementation of
differentiation cocktail with DHT (ixr+dex+DHT).
Figures 4, 5A, and 5B supported the role of both dex and GR
action in driving AR induction in human adipocytes. Although1130 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201there was no clear correlation between AR and PPARg (Fig-
ure 3A), we detected a positive correlation between AR and
GR (PrMIX = 0.57) as shown in Figure 5C for preadipocytes
differentiated (ixr+dex; MIX) for 96 hr. At the single-cell level,
we divided the population into low and high GR-expressing cells
based on the median level of GR detected after treatment with
complete differentiation cocktail (ixr+dex) (Figure 5D). Although
median AR levels varied as a function of DHT treatment,
temporal analysis of the two subpopulations showed cells with
higher GR were associated with both higher lipid (Figure 5E)
and AR (Figure 5F) levels. These results suggest that GR (Fig-
ure 4) and dex (Figure 5) are needed to regulate AR at the2 Elsevier Ltd All rights reserved
Figure 4. siRNA-Mediated Depletion of GR Inhibits AR Upregulation in Differentiating Human Adipocytes
(A) Preadipocytes were transfected with scrambled (scrambled siRNA) or siRNA to GR (GR siRNA) for 48 hr followed by induction of differentiation (+MIX) and
HTM. Scale bar, 50 mm.
(B–D) HCA detection of (B) nuclear GR, (C) lipid accumulation, and (D) nuclear AR after siRNA transfection (n R 4 experiments) by immunofluorescence and
lipid labeling.
(E) qPCR was used to validate HCA measurements of GR knockdown and downstream effects on AR, lipid accumulation, and target gene expression: GR, AR,
PPARg2, FABP4, CIDEC, and FKBP5. RNAwas isolated from two independent experiments. Asterisks indicate measured variables statistically different from the
nontargeting siRNA control at the 95% confidence level (*p < 0.05). Error bars, SEM.
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expression is increased by dex and GR, we reasoned AR might
adopt a repressive conformation that abrogates its ability to
prevent adipocyte differentiation.
Adipocyte Differentiation Reagents Modulate
AR Conformation
The N-terminal activation function 1 (AF-1) and the C-terminal
ligand-dependent (AF-2) domains of AR are largely inactive in
the absence of ligand. In the presence of agonists, AR adopts
a conformational change allowing communication between
AF-1 and AF-2 and subsequent transcriptional activation
(Kemppainen et al., 1999; Langley et al., 1995; Schaufele
et al., 2005). To test our hypothesis regarding inhibition of AR
activity, we used a fluorescence resonance energy transfer
(FRET)-based assay (Jones et al., 2009; Klokk et al., 2007;
Schaufele et al., 2005) to determine the effect of differentiationChemistry & Biology 19, 1126–114cocktail on the intramolecular interaction between CFP-AF-1
and YFP-AF-2 domains in full-length AR. In this assay, agonist
binding induces a conformational change that brings the cyan
fluorescent protein (CFP) and yellow fluorescent protein (YFP)
into close proximity, enabling energy transfer, which precedes
nuclear translocation and transcriptional activity. In these
experiments, we transiently expressed a CFP-AR-YFP fusion
protein in HeLa and exposed the cells to 10 nM DHT, EtOH
(vehicle), 10 mM OHF, or MIX for 20 hr (Figure 6A). To detect
effects on androgen-induced conformation, OHF/DHT and
MIX/DHT treatments were applied. Figure 6B shows that DHT
markedly induced nuclear translocation, altered subnuclear
localization, and increased energy transfer (7.5-fold), which
is indicative of intramolecular events bringing the AF-1 and
AF-2 domains into close proximity (Figure 6B). Compared to
vehicle, OHF stimulated a lesser increase in FRET (2.4-fold),
while MIX showed no significant change. However, treatment1, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1131
Figure 5. AR Expression Is Correlated with Dexamethasone-Driven Adipocyte Differentiation
(A) Preadipocytes were differentiated (ixr: insulin/IBMX/rosiglitazone) for 96 hr in the presence or absence of dexamethasone (dex) ± 10 nMDHT. qPCRwas used
to measure mRNA expression for GR, AR, PPARg2, FABP4, CIDEC, and FKBP5. RNA was isolated from two independent experiments.
(B) In parallel experiments, effects of dex and DHT on AR induction and lipid accumulation were evaluated by HCA. Subsequent to the treatments, GR and AR
were detected by immunofluorescence in combination with lipid labeling.
(C) Cell-to-cell correlation between AR and GR was monitored. One representative experiment is shown for cells differentiated with standard cocktail (MIX) for
96 hr. Individual cell measurements of nuclear GR and AR were normalized to the median intensity of standard differentiation cocktail (ixr+dex; MIX) at 96 hr. GR
normalization of all treatments set a threshold (dotted line) to subdivide cells into GRlo and GRhi subpopulations.
(D–F) The median single-cell intensities of (D) GR, (E) lipid content, and (F) AR were determined for the GRlo and GRhi populations at 96 hr (*p < 0.05, nR 400 cells
per treatment). Error bars, SEM.
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blocked the androgen-induced conformational change by
43% and 56%, respectively. These experiments suggested1132 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201that one or more components of adipocyte differentiation cock-
tail antagonize AR activity by blocking ligand-induced N/
C-terminal interactions.2 Elsevier Ltd All rights reserved
Figure 6. Human Adipocyte Differentiation
Alters the Conformation of AR
(A) HeLa cells transiently transfected with CFP-
AR-YFP were treated with vehicle, 10 mM OHF, or
differentiation media (MIX) in the presence or
absence of 1 nM DHT for 20 hr. Scale bar, 10 mm.
(B) FRET imaging was used to determine AR
conformation (nR 10 cells per condition).
(C) An N-terminal region containing AR 1-660 was
fused to the VP16 TAD, while a C-terminal region
containing AR 624-919 (wild-type) was fused to
the to the Gal4-DBD domain. HeLa cells were
cotransfected with AR fragments and reporter
constructs as described in Experimental Proce-
dures. After 12 hr of transfection, cells were tryp-
sinized and equally seeded into 96-well plates.
Cells were allowed to reattach and subsequently
treated with dexamethasone (500 nM), IBMX (250
uM), insulin (200 nM), rosiglitazone (3 mM), MIX,
and AR ligands, alone or in the presence of 0.1 nM
DHT. After 24 hr of treatment, luciferase activity
was detected. Data represents the units of firefly
luciferase corrected for the units of renilla lucif-
erase detected in the same plate. Shown is one
representative experiment from four replications.
p < 0.05 was considered significant for treatments
compared to vehicle (#) or DHT (*) treatments.
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hybrid assay to determine whether AR N/C-terminal domain
interactions might be altered by treatment with each component
of the differentiation cocktail. As the agonists bind the ligand-
binding domain of AR, the AR (1-660)-VP16 and AR (624-919)-
Gal4 fusion proteins become close enough to activate luciferase
activity driven by theGal4-VP16 interaction (Langley et al., 1995).
Expression of individual VP16 or Gal4 plasmids were used as
negative controls. When we treated cells with individual or all
components combined (MIX), the basal AF-1/AF-2 interaction
was not affected (Figure 6C). In complementary experiments,
we also treated cells with individual or all components (MIX)
combined in the presence of 0.1 nM DHT. Similar to OHF,
dexamethasone and MIX inhibited DHT-induced N/C-terminal
interaction (Figure 6C). Thus, the next step was to determine
the extent to which AR transcriptional activity was inhibited by
adipocyte differentiation signals.
Inhibition of AR Transcriptional Activity by Chemical
Inducers of Adipocyte Differentiation
As MIX components were shown to alter the conformation of
AR, we next assessed whether AR translocation and transcrip-
tional activity were similarly modulated. To do this, we createdChemistry & Biology 19, 1126–1141, September 21, 2012 ªa transcriptional biosensor cell line based
on a parental green fluorescent protein
(GFP)-AR HeLa model described pre-
viously, which faithfully expresses AR
target genes in response to agonist treat-
ments (Szafran et al., 2008). We stably
incorporated an ARR2PB-dsRED2-skl
reporter construct, which is responsive
to AR agonists and inhibited by antago-nists (in competition experiments), including MIX (Figure 7A).
After image processing, HCA was used to simultaneously quan-
tify GFP-AR subcellular localization (% nuclear AR) (Figure 7B),
total AR expression (Figure 7C), and ARR2PB-dsRED2-skl
reporter activity (Figure 7D) for compound concentrations used
in differentiation cocktail. As expected (Szafran et al., 2008),
DHT elicited significant, dose-dependent increases in all three
features. Dexamethasone, IBMX, and MIX induced AR trans-
location (Figure 7B), while insulin and MIX upregulated total
AR levels (Figure 6C). Although some of the components
together (MIX) or individually affected total AR and AR trans-
location, none increased AR transcriptional activity (Figure 7D).
When treatments were performed in the presence of 1 nM DHT
(+), several effects were observed. First, insulin, IBMX, and rosi-
glitazone decreased androgen-induced AR translocation
compared to 1 nM DHT (Figure 7B). Second, IBMX, dexametha-
sone, and rosiglitazone inhibited DHT-induced reporter activity
(Figure 7C).
Although our three basic measurements reporting important
mechanisms of AR activity were informative (Figures 7B–7D),
they do not encompass the wealth of phenotypic data available
in the images, which can characterize the biological phenotypes
caused by the different compound treatments. Extending2012 Elsevier Ltd All rights reserved 1133
Figure 7. Adipocyte Differentiation Reagents Repress AR Transcriptional Activity
(A–D) GFP-AR:ARR2PB-dsRED2-skl double-stable HeLa cells were used to evaluate effects of differentiation reagents (48 hr) on GFP AR nuclear translocation,
total AR levels, and androgen-dependent reporter activity encoded by the expression of peroxisome-targeted dsRED2. After treatment, experiments were
processed for automated microscopy, imaged, and segmented into single-cell regions for feature extraction (A). Response data are depicted for (B) nuclear
translocation, (C) total AR, and (D) ARR2PB-dsRED-skl activity for the indicated treatments. Experiments were performed in the presence and absence of 1 nM
DHT. One representative experiment from three replications is shown; p < 0.05 was considered significant for treatments compared to vehicle (#) or DHT (*)
treatments.
(E and F) In (E), SVM allowedmore sensitive detection of AR repression by adipocyte differentiation components. An SVMclassifier was trained to recognize OHF,
DHT, or DHT/OHF patterns and applied to cell-level responses (from the DAPI, GFP-AR, and ARR2PB-dsRED2-skl channels). Cells were automatically classified
into DHT, OHF, or DHT/OHF treatment groups based on selected, robust subcellular measurements used by the SVM classifier. For each subplot, the abscissa
represents compound treatments, while the ordinate denotes the percentage of cells assigned to each population. To validate effects on AR-mediated
Chemistry & Biology
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estrogen receptor responses (Ashcroft et al., 2011), we identified
single-cell-level features that classified MIX components based
on their similarity to control treatments. We generated a control
data set consisting of cells treated with 10 nM DHT, 10 mMOHF,
or 1 nMDHT + 10 mMOHF. After image processing, we extracted
intensity- and morphology-based features (276 measurements
per cell) from the GFP-AR and ARR2PB-dsRED2-skl channels.
These measurements include mechanistic features (e.g., GFP-
AR levels and localization), cytological features (e.g., GFP-AR
nuclear variance (Szafran et al., 2008)) and statistical features
(e.g., cytoplasmic ARR2PB-dsRED2-skl kurtosis). We processed
the features and applied stepwise discriminant analysis (Jenn-
rich, 1977), which selected 32 features especially useful in distin-
guishing between control treatments (Table S1). Finally, we
trained a classifier on the control data using the SDA-selected
features, whichwas used to classify the cells from the compound
treatments. This classification framework was validated on the
control data to assess classifier performance (Table S1). From
classification, we were able to identify the percentage of cells
exhibiting AR agonism or antagonism given a particular treat-
ment (Figure 7E). It is interesting that, by incorporating effects
on GFP-AR protein levels, localization, subnuclear pattern, and
reporter levels, this approach had high enough sensitivity to
detect effects of all MIX components in the absence of DHT,
which was impossible by CFP-AR-YFP (Figure 6B) or mamma-
lian two-hybrid assays (Figure 6C).
Figure 7E suggested that each MIX compound redistributed
cell populations to predominantly OHF or DHT/OHF phenotypes.
Also, during DHT treatment, individual addition of IBMX, insulin,
or rosiglitazone decreased the number of cells classified as
agonist (DHT) and increased the number of cells classified as
antiandrogen (DHT/OHF). Furthermore, MIX reflected the indi-
vidual components andwas classified as a predominantly antag-
onist treatment (e.g., OHF alone or DHT/OHF) with a complete
loss of the DHT class.
To complement our findings in the GFP-AR:ARR2PB-dsRED2
biosensor cell line and verify the inhibition of AR transcriptional
activity by adipocyte differentiation reagents, we expressed
the AR-specific ARR2PB-luciferase reporter plasmid (Schoen-
makers et al., 2000) in terminally differentiated human adipo-
cytes. We found nuclear AR was increased by 2.84-fold in cells
differentiated for 7 days (MIX, +; DHT, ), while not significantly
increased compared to 96 hr (Figure 3D). Treatment with MIX for
2 additional days (MIX, ++; DHT,) did not significantly increase
nuclear AR. An additional 2 days of treatments with androgen
alone (MIX, +; DHT, +), or androgen and MIX (DHT, +; MIX, ++),
resulted increased nuclear AR 5.8-fold and 8.1-fold compared
to vehicle treatment (MIX, ; DHT, ), respectively (Figure 7F).
Concomitantly, when ARR2PB-luciferase was expressed in
terminally differentiated adipocytes (7 days), androgen-induced
transcriptional activity was decreased when cells were treated
with both DHT and MIX for an additional 2 days (Figure 7G).transcription in primary cells, human preadipocytes were differentiated (MIX)
b-galactosidase (b-gal). Subsequently, cells were treated with 10 nM DHT alon
treatments on (F) AR levels were evaluated by HCA (nR 100 cells per condition
(G) ARR2PB luciferase activity was measured and normalized to b-gal (n = 3 ± S
See also Table S1.
Chemistry & Biology 19, 1126–114These combined experimental approaches show that, in human
preadipocytes, AR is upregulated by dexamethasone activation
of GR, while also transcriptionally inhibited to putatively promote
features of adipocyte maturation.
DISCUSSION
The identification of modulators of human adipocyte gene
expression is central to understanding the mechanisms of
obesity. Our comparative analysis of the transcriptomes from
differentiated human adipocytes and terminally differentiated
mouse 3T3-L1 adipocytes (Schupp et al., 2009) suggested that
early, significant AR upregulation and function is a specific
feature of the human preadipocyte differentiation model (Fig-
ure 1). Recently, AR was reported to be expressed at low (Fu
et al., 2005) or undetectable (Lahnalampi et al., 2010) levels in
3T3-L1 cells. In our experiments, DHT only inhibited mouse
3T3-L1 differentiation when AR was exogenously expressed by
lentivirus, whereas lipid accumulation was clearly reduced in
human adipocytes 4 days postinduction (Figure 2). Inhibition of
human adipocyte differentiation by DHT was further marked by
parallel increases in AR protein levels and repression of adipo-
cyte-specific markers (Figure 3) at the protein (PPARg) and
gene (FASN,PPARg,ADFP, andC/EBPa) levels. Indeed, consis-
tent with our effects of DHT on lipid accumulation, DHT has
also been found to reduce expression of ACC1 and DGAT2,
key enzymes in triacylglycerol synthesis (Gupta et al., 2008).
Upon ligand binding and conformational change, AR, proges-
terone receptor (PR), mineralocorticoid receptor (MR), and GR
can regulate gene transcription by binding a consensus GGT/
AACAnnnTGTTCT hormone response element (HRE) (Lieberman
et al., 1993; Lombe`s et al., 1993; Nordeen et al., 1990; Roche
et al., 1992). Due to the shared consensus binding motifs for
AR, GR, MR, and PR, these receptors can affect the transcrip-
tional activity and regulation of other Type 1 members. For
example, both PR and AR have been shown to inhibit GR
transcriptional activity at HREs (Archer et al., 1994; Chen et al.,
1997; Yen et al., 1997). Therefore, the common DNA-binding
site that AR, MR, PR, and GR share provides a capacity to
mediate cellular responses through intrareceptor crosstalk.
Specifically, recent work has shown that dexamethasone
induces GR binding upstream of AR (Reddy et al., 2009). We
therefore propose that dexamethasone mobilizes GR to launch
adipocyte differentiation, positioning GR as a central regulator
of early differentiation and AR expression. Our work shows
that GR (Figure 4), regulated by dexamethasone (Figure 5), is
required to induce AR expression and regulate the adipocyte
phenotype. Novel to the understanding of theGR/AR interrelated
gene network, we also established nuclear GR levels are tightly
correlated with lipid accumulation (Figure 5D) and nuclear AR
(Figure 5E) at the single-cell level during differentiation.
We sought to identify further elements of the AR regula-
tion circuit by analyzing effects of adipocyte differentiationfor 7 days followed by transfection of cells with pARR2PB-luciferease and
e or MIX ± 10 nM DHT for 48 hr in serum-containing media. Effects of these
).
EM). Scale bar, 20 mm.
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adipocyte differentiation reagents reduce androgen-dependent
AR N/C-terminal interactions (Figures 6A and 6B), inducing
quantitatively similar results as a classic antiandrogen (OHF).
Second, we used a novel AR fluorescent biosensor cell line
and HCA to identify how individual components of adipocyte
differentiation cocktail antagonize AR activity and affect
transcriptional competence (Figures 7A–7E). Coupled with a
machine-learning algorithm to classify subtle phenotypes into
DHT, OHF, and DHT/OHF treatments, we were able to able to
establish rosiglitazone and dexamethasone as potent inhibitors
of AR activity. Androgen-regulated AR transcriptional activity in
human adipocytes was decreased by differentiation cocktail
(Figure 7G), which validated our findings in GFP-AR:ARR2PB-
dsRED2 biosensor cells. Previous studies have shown dexa-
methasone and glucocorticoids can inhibit androgen action
and downregulate AR activity by competing for androgen
response elements (Burnstein et al., 1995; Davies and Rush-
mere, 1990) without high affinity binding to AR (Wilson and
French, 1976). Rosiglitazone, on the other hand, suppresses
AR-regulated genes, including the ARR2PB composite reporter,
by reduction of agonist-induced receptor binding to DNA (Moss
et al., 2010; Yang et al., 2006).
Clinical and epidemiological data imply the existence of
a negative cycle between circulating testosterone and obesity,
although AR mRNA is unaltered with increasing BMI, indepen-
dent of sex (Wake et al., 2007). Indeed, further supporting inhibi-
tion of AR transcriptional activity during fat maturation, each MIX
component has been shown to induce adipogenesis in vivo
(De Vos et al., 1996; Fujikura et al., 2005; Madsen et al., 2008;
Masuzaki et al., 2001, 2003). Furthermore, testosterone produc-
tion is suppressed by visceral obesity (Stanworth and Jones,
2009), and patients with visceral obesity and the metabolic
syndrome have higher incidence of hypogonadism (Gould
et al., 2007).
Androgens have been thought to block adipocyte differentia-
tion (Blouin et al., 2009a, 2010; Gupta et al., 2008; Singh et al.,
2003, 2006) by upregulation of Wnt target genes (Singh et al.,
2006). In our transcriptome analysis, we detected 51 Wnt target
genes exhibiting at least 2-fold change (Supplemental Excel File
S1), including targets upregulated by testosterone (CD44, FST,
LEF1). Ninety-two percent of the Wnt target genes were down-
regulated between preadipocyte and terminal differentiation,
which may correspond to decreased AR activity. PPARg (Liu
and Farmer, 2004; Waki et al., 2007) and GR (Bujalska et al.,
2006) activation repress Wnt target genes. Thus, subtle alter-
ations in the activity of proadipogenic transcription factors may
sustain repression of Wnt signaling via inhibition of AR.
Recent studies (Veilleux et al., 2012) support our findings
by showing androgens and glucocorticoids exhibit extensive
crosstalk to direct lipid storage in a sex- and depot-specific
manner by increasing androgen metabolism. Although excess
glucocorticoids and androgens can profoundly affect adipocyte
function and promote altered metabolism, additional studies
are required to better understand how selective manipulation
of the AR/GR axis controls fat deposition and improves overall
lipid profiles. Finally, the experiments described in this article
propose a feed-forward loop whereby glucocorticoids activate
GR to promote AR expression yet inhibit AR activity. Because1136 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201peripheral fat tissue contains the enzymatic machinery to syn-
thesize GR agonists, it is possible that these steroids produced
in loco are responsible for AR antagonism and activation of lipid
storage genes that contributes to maintenance of proper energy
balance (Lee et al., 2008).
SIGNIFICANCE
The characterization of genes associated with human
adipocytes is fundamental to understanding the pathogen-
esis of obesity. Given this need, we identified specific genes
associatedwith theprimary, early humanadipocyte differen-
tiation program that are not sufficiently expressed in 3T3-L1.
In support of recent epigenomic analyses of mouse 3T3-L1
and human adipocyte systems (Mikkelsen et al., 2010; Soc-
cio et al., 2011), the 3T3-L1 and human adipocyte transcrip-
tomes are also dissimilar. In this study, we used high content
analysis and quantitative imaging to show that in vitro
human adipocytes express ARmRNA and protein, regulated
by both GR and dexamethasone action, and GR and AR
levels are directly correlated. Of specific importance, we
used novel image analysis tools to establish antagonism of
AR by adipocyte differentiation components, and identified
dexamethasone as the dominant inhibitor of AR transcrip-
tional activity. AR mRNA is not negatively correlated with
body mass index (Wake et al., 2007), suggesting that obesity
does not downregulate AR but negatively modulates its
activity. Our data suggest that GR and corticosteroids can
both positively regulate AR expression while simultaneously
decreasing AR activity and alter androgen effects on energy
storage. Since androgens favorably direct muscle differenti-
ation (Singh et al., 2003), regulate muscle mass (Chambon
et al., 2010), and increase lean body mass in aging males
(Tenover, 1992) and females (Rariy et al., 2011), the use of
selective GR or AR modulators in combination may play
a role in alleviating the consequences of obesity.
EXPERIMENTAL PROCEDURES
Primary Cell Culture and Differentiation
Cryopreserved, subcutaneous primary human preadipocytes from normal
female donors with an average body mass index of 27.51 were provided by
Zen-Bio Inc. (Research Triangle Park, NC, USA). Cells were received at
passage 2, and experiments were performed before passage 10. Experiments
were performed using pooled human preadipocytes from five individual female
donors (Lot SL0033). Both human preadipocytes and 3T3-L1 cells were main-
tained at 5% CO2/37
C in Dulbecco’s modified Eagle medium (DMEM)/F12
(Mediatech, Manassas, VA, USA) with 10% fetal bovine serum (FBS; Gemini
Bio-Products, West Sacramento, CA), 100 U/ml penicillin, 100 mg/ml strepto-
mycin (growth media). Medium was replaced during routine maintenance
every 2 days.
Confluent cells were differentiated using growth media supplemented with
100 nM human insulin, 0.250 mM 3-isobutyl-1-methylxanthine (IBMX),
500 nM dexamethasone, and 3 mM rosiglitazone (BRL49653, Cayman Chem-
ical Company, Ann Arbor, MI, USA). IBMX, insulin, and dexamethasone were
purchased from Sigma Chemical Company (St. Louis, MO, USA).
DNA Microarrays
Microarray analysis was performed using the Illumina Sentrix Beadchip Array
(Human HT-12) containing 48,000 probe sequences that spans the human
transcriptome. Adipocytes were differentiated for the indicated periods and
washed, and total RNA was prepared using RNeasy (QIAGEN, Valencia, CA,2 Elsevier Ltd All rights reserved
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grams of total RNA were amplified and purified using Illumina TotalPrep
RNA Amplification Kit (Ambion, Catalog # IL1791) following themanufacturer’s
instructions. The first strand of cDNA was synthesized by incubating RNA with
T7 oligo(dT) primer and reverse transcriptasemix at 42C for 2 hr. RNase H and
DNA polymerase master mix were immediately added into the reaction mix
following reverse transcription and were incubated for 2 hr at 16C to synthe-
size second strand cDNA. In vitro transcriptionwas performed and biotinylated
cRNA was synthesized by a 16 hr amplification with dNTP mix containing
biotin-dUTP and T7 RNA polymerase. Amplified cRNA was subsequently
purified, and the concentration was measured by NanoDrop ND-1000 Spec-
trophotometer (NanoDrop Technologies, Wilmington, DE, USA). An aliquot
of 1.5 mg of amplified products was loaded on to Illumina Human HT-12 Bead-
chips and hybridized at 58C for 17 hr, washed, and incubated with straptavi-
din-Cy3 to detect biotin-labeled cRNA on the arrays. Arrays were dried and
scanned using a BeadArray Reader (Illumina, San Diego, CA, USA). Each
microarray was performed, minimally, with three independent RNA isolates.
We performed microarrays at 7 time points: Day 0 (n = 5), Day 1 (n = 4),
Day 2 (n = 4), Day 3 (n = 4), Day 4 (n = 4), Day 7 (n = 3), and Day 14 (n = 4).
Microarray Analysis
Background subtracted and quantile normalized gene expression values were
calculated using Illumina BeadStudio Software. Differential gene expression
was calculated by fitting a linear model to a group means parameterization
coupled to a secondary fit of all possible pairwise comparisons equating to
an ANOVA using R2.10 and the Limma 2.19 analysis package. Controlling
the false discovery rate (FDR) was used to correct for multiple testing. Genes
presented in the heatmap are transcripts with a minimum 4-fold change at any
given contrast (FDR q < 0.0001). Samples were clustered using complete
agglomerization and Euclidean distance. Rows were scaled to have a mean
of 0 and SD of 1. 3T3-L1 gene expression data was obtained from
GSE14004 (Schupp et al., 2009).
RNA Extraction and qPCR Analysis
Total RNA was extracted from cells using the RNeasy kit (QIAGEN, German-
town, MD, USA), following the manufacturer’s instructions. To measure rela-
tive mRNA expression, qPCR was performed using the Taqman RT-PCR
one-step master mix in conjunction with an ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA). Each sample was tested in dupli-
cate in two independent experiments. b-actin and TATA box-binding protein
were used as invariant controls. TaqMan Gene Expression Assays were
used for the following human genes: CEBPa, Assay ID Hs00269972_s1;
PPARg2, Assay ID Hs01115513_m1; GR, Assay ID Hs00353740_m1; CIDEC,
Assay ID Hs01032998_m1; FABP4, Assay ID Hs01086177_m1; FKBP5, Assay
ID Hs01561006_m1; AR, Assay ID Hs00171172_m1. The following primer and
probe sets were used to detect human (h) hFASN, hSRC-3, and hADFP.
hFASN: cggagtgaatctgggttgat(F), caggcacacacgatggac(R), Roche Universal
Probe Library probe #11 (probe); hSRC-3: ggacctggtaagaaggtgtattcag (F),
tgcctcttagcataggacacaga (R), tccatgcgcagcatgaaggaga (probe); hADFP:
gtgactggcagtgtggagaag (F), tccgactccccaagactgt (R), ccaagtctgtggtcagtgg
cagca (probe). Murine FABP4 and PPARg2 were detected with the following
primer and probe sets: mPPARg2: gaaagacaacggacaaatcacc (F), gggggtga
tatgtttgaacttg (R), Roche Universal Probe Library probe #7 (probe); mFABP4:
aagagaaaacgagatggtgacaa (F), cttgtggaagtcacgccttt (L), Roche Universal
Probe Library probe #31 (probe).
siRNA Transfection
Before cell plating, optical quality 96-well plates (Greiner SensoPlate Plus,
Monroe, NC, USA) were coated with 50 ml of FBS (Gemini Bio-Products)
overnight at 37C. Confluent preadipocytes were transfected with GR siRNA
(QIAGEN, Germantown,MD, USA) or mismatch control at a final concentration
of 20 nM using Dharmafect transfection reagent (Dharmacon, Lafayette, CO,
USA). After transfection, cells were incubated for 48 hr at 5%CO2/37
C before
induction of differentiation for 96 hr.
Antibodies
The following antibodies were purchased from commercial sources and used
for immunofluorescence and estern blotting: rabbit polyclonal AR (N-20, SantaChemistry & Biology 19, 1126–114Cruz Biotechnology, Santa Cruz, CA, USA), rabbit monoclonal PPARg (Cell
Signaling, Danvers, MA, USA), GR (Genetex, Irvine, CA, USA), and mouse
monoclonal PPARg (clone E-8, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Mouse monoclonal antibody to AR (AR-441) (Nazareth et al., 1999)
was kindly provided by Dean Edward and Nancy Weigel (Baylor College of
Medicine, Houston, TX, USA).
Western Blotting
Cells were collected by scraping, and lysed in RIPA buffer supplemented
with the appropriate proteinase and phosphatase inhibitors. Protein concen-
tration was standardized by BCA assay. Western blot analysis was performed
with whole cell lysates run on 4%–12% Bis-Tris NuPage (Millipore, Bedford,
MA, USA) gels and transferred onto Immobilon-P Transfer Membranes
(Millipore). Membranes were blocked 1 hr with 5%milk (in Tris-buffered saline
[TBS] with 0.1% Tween-20). Primary antibodies were incubated overnight
at 4C, followed by secondary antibodies for 1 hr at room temperature.
Immunoreactive bands were visualized by SuperSignal West Femto chemilu-
minescence reagents (Pierce, Rockford, IL, USA). All membranes were then
subjected to stripping buffer (Pierce) for 30 min at room temperature,
reblocked, and reprobed for b-actin (mouse monoclonal, Sigma Chemical
Co.) as a loading control.
Immunofluorescence
For fluorescence detection of antibodies and neutral lipid content in multiwell
plates, the following protocol was carried out on the BioMek NX (Beckman
Coulter, Fullerton, CA, USA). Well plate systems used were: 96-well and
384-well (Greiner Sensoplate Plus, Monroe, NC, USA). Aspirations and plate
washes were performed with an ELx405 (BioTek, Winooski, VT, USA). After
differentiation, media was aspirated and 4% formaldehyde (sold as ultrapure
paraformaldehye, Electron Microscopy Sciences, Hatfield, PA, USA) in PBS
was immediately added for 30 min at room temperature. Plates were then
quenched with 100 mM ammonium chloride. After quenching, plates were
washed three times with TBS. Fixed adipocytes were permeabilized with
0.1% Triton X-100 in TBS for 10 min and washed three times with TBS.
Nonspecific antibody binding was blocked by preincubating for 30 min in
2% bovine serum albumin in TBS/0.01% saponin (which was also used as
an antibody diluent) at room temperature. Antibodies were then diluted at
a 1:200 concentration in antibody diluent and incubated overnight at 4C.
Subsequently, plates were washed with TBS and incubated with secondary
antibodies for 1 hr at room temperature. AlexaFluor 647-conjugated antimouse
and AlexaFluor 568-conjugated antirabbit secondary antibodies (Molecular
Probes, Invitrogen) were used. Cells were then washed three times and
incubated with CellMask Blue (1 mg/ml, Invitrogen, a general protein dye),
LipidTOX green (1:1,000, Invitrogen, a nonpolar lipid-binding dye), and DAPI
(10 mg/ml, a DNA-specific dye) in PBS for 45 min at room temperature. Dyes
were then aspirated, PBS/0.01% azide was added, and plates were imaged
immediately.
Imaging and Microscopy
For high-speed image acquisition for subsequent analysis, cells were imaged
using the Cell Lab IC-100 Image Cytometer (IC-100; Beckman Coulter)
equipped with a Nikon S Fluor 203/0.75NA objective. The imaging camera
(Hamamatsu; Bridgewater, NJ, USA) was set to capture eight bit images at
2 3 2 binning (672 3 512 pixels, 0.684 3 0.684 mm2/pixel) with five images
captured per field (DAPI, CMBl, LipidTOX, A568 and A647 secondary anti-
bodies). In general, 12–16 images were captured per well for image analysis.
Experiments performed in stable HeLa cell lines and 3T3-L1 were imaged
with a 403/0.90NA objective.
Image Processing
Images were analyzed using custom algorithms developed with the Pipeline
Pilot (v7.5) software platform (Accelrys; San Diego, CA, USA) in a similar
workflow as previously described (Hartig et al., 2011; Szafran et al., 2008).
After background subtraction, nuclear and cell masks are generated using
a combination of nonlinear least-squares and watershed-from-markers image
manipulations of the DAPI images. Cell populations were filtered to discard
events with cell aggregates, mitotic cells, apoptotic cells, cellular debris, or
poor segmentation. Applied gates were based upon nuclear area, nuclear1, September 21, 2012 ª2012 Elsevier Ltd All rights reserved 1137
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the population of segmented cells. All events with whole cell masks bordering
the edge of the image were additionally eliminated from analysis. Postanalysis
measurements were exported to spreadsheet software (Microsoft Excel) for
further analysis.
Production of Lentiviral Particles
Human AR cDNAwas cloned into the lentiviral expression vector pCDH–CMV-
MCS-EF1-Puro (System Biosciences, Mountain View, CA, USA) by Xba I/Nhe I
digestion. Pseudolentiviruses were produced in 293TN cells by cotransfecting
lentiviral expression constructs and the pPACK packaging plasmid mix
(System Biosciences). Pseudoviral particles were harvested 48 hr posttrans-
fection and were concentrated using PEG-it virus precipitation solution kit
(System Biosciences).
FRET Imaging
CFP/YFP FRET experiments were performed using a CFP-AR-YFP construct
and reagents kindly provided by Fred Schaufele (University of California,
San Francisco) and Fahri Saatcioglu (University of Oslo). CFP-AR-YFP was
transiently expressed in HeLa grown on standard 12 mm glass coverslips.
Constructs were transfected using Lipofectamine 2000 (Invitrogen). Media
was removed and replaced with fresh DMEM/F12 with 5% FBS 24 hr post-
transfection. Cells were then treated overnight with compounds (20 hr)
prepared in growth media (DMEM/F12, 5% FBS). Treatment was followed
with these steps: fixation, 4% PFA (30 min); quench, 100 mM NH4Cl
(10 min); and mount with SlowFade Gold (Invitrogen). After fixation, cells
were washed with PBS++ three times, while all other wash steps were per-
formed with PIPES/HEPES/EGTA/MgCl2 (PEM) buffer, prepared at a final pH
of 6.8.
FRET imaging was performed as described previously with the DeltaVision
Core Image Restoration Microscope (Applied Precision, Issaquah, WA, USA).
Z-stacks were imaged at 0.2 mm separation and a frame size of 1,0243 1,024
pixels at 13 1 binning with an Olympus IX71microscope using a 603, 1.42 NA
Plan Achromat objective (Olympus, Center Valley, PA, USA), and a Photomet-
rics CoolSnap HQ2 CCD camera. Filter sets were as follows, with a dichroic to
split CFP and YFP: excitation 430 nm/emission 470 nm (CFP), excitation
500 nm/emission 535 nm (YFP), and excitation 430 nm/emission 535 nm
(FRET). After deconvolution (Softworx, Applied Precision), FRET calculations
were performed using the Applied Precision FRET user interface. FRET
measurements on individual nuclei were acquired on maximum intensity
projections of the derived FRET image. Spectral bleed through was corrected
for by acquiring specimens containing only CFP-AR and YFP-AR. Standard
values for a and b coefficients were 0.6 (CFP) and 0.12 (YFP) acquired from
single donor/acceptor plasmid expression experiments. Additional and sup-
porting analyses were performed using PixFRET (Feige et al., 2005).
AR NH2-COOH Domain Interaction Assay
An interaction between COOH terminal AF2 (activation function 2) and NH2
terminal sequence F23XXLF27 was measured using the CheckMate/Flexi
Vector Mammalian Two-Hybrid System (Promega, Madison, WI, USA). A
segment containing AR 1-660 was fused to the VP16 TAD domain of plasmid
pFN10A, while segments AR 624-919 were fused to the to the Gal4-DBD
domain of plasmid pFN11A. One day before transfection, 1.53 106 HeLa cells
were seeded into a 60-mm dish. Cells were cotransfected with 1.3 mg of
pFN11A-AR624-919, 1.3 mg of pFN10A-1-660, 1.3 mg of pGL4.31 (containing
five GAL4 binding sites upstream of a minimal TATA box, which is upstream
of a firefly luciferase gene that acts as a reporter for interactions between
proteins), and 1 ng of phRL-TK carrying the Renilla luciferase gene. After
12 hr of transfection, cells were trypsinized and equally seeded into a 96-
well plate. Multireplicate detection of NH2-COOH interaction was evaluated
in ligand competition experiments where adipogenic compounds and OHF
were titrated against 0.1 nM DHT. After 24 hr of treatment, luciferase activity
was assayed with the Promega Dual Glo assay kit, using a luminometer
(PerkinElmer). Data represent the units of firefly luciferase corrected for the
units of renilla luciferase detected in the same plate. As controls to account
for basal activity of pFN11A-AR624-919 and pFN10A-AR1-660, parallel ex-
periments were performed with each plasmid expressed individually.1138 Chemistry & Biology 19, 1126–1141, September 21, 2012 ª201Luciferase Expression Experiments
We used replication deficient adenoviruses coupled with polylysine (Allgood
et al., 1997) to express pARR2PB-luciferase in human preadipocytes. Reporter
gene activity was detected using the Promega Luciferase Assay Kit. Relative
luminescence units were normalized to b-galactosidase activity using a stan-
dard 2-Nitrophenyl b-d-galactopyranoside (Sigma) colorimetric assay.
GFP-AR:ARR2PB-dsRED2-skl Biosensor Experiments
We developed a stable cell line for cell-based HCA of AR translocation and
reporter activity under treatment with adipogenic compounds. The parental
GFP-AR HeLa cell line (Szafran et al., 2008) was infected with a lentivirus
encoding a pARR2PB-dsRED2skl reporter construct, based on the AR-
responsive composite probasin promoter. This reporter encodes a dsRED2
protein (Clontech) fused at the C terminus with a peroxisome targeting
sequence (SKL, serine, lysine, leucine) that serves to localize and concentrate
the fluorescence signal. Antibiotic-resistant cultures were selected with both
puromycin (1.5 mg/ml) and hygromycin (200 mg/ml) for 2 weeks. Subsequently,
clones were single cell sorted by FACS where clones were identified based
on GFP-AR and ARR2PB-dsRED2-skl responsiveness (e.g., low GFP/high
dsRED2). Single-cell clones in phenol-red-free DMEM (Mediatech) with
5% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 1.5 mg/ml puromycin,
and 200 mg/ml hygromycin. One single-cell clone (GFP-AR:ARR2PB-
dsRED2skl) that exhibited maximal DHT-responsive reporter activity was
used for detecting androgenic effects of rosiglitazone, dexamethasone,
insulin, IBMX, and OHF.
Before experiments, 384 well plates (Greiner Sensoplate Plus) were coated
with FBS overnight. Cells were plated (4,000 cell/well), after excess FBS
was removed from each well, using the TiterTek Multi-Drop Plus (TiterTek,
Huntsville, AL, USA). GFP-AR:ARR2PB-dsRED2skl cells were seeded in
antibiotic-free, phenol-red-free DMEM containing 5% charcoal-stripped,
dialyzed (SD) FBS and incubated 48 hr. Cells were then exposed cells to single
doses of each compound in the presence or absence of 1 nM DHT. Vehicle
(EtOH), 10 nM DHT, 10 mM OHF, and 1 nM DHT/10 mM OHF treatments
functioned as controls, each in individual columns. After compound addition,
cells were incubated 48 hr to allow for simultaneous detection of AR trans-
location and reporter expression. Plates were processed for imaging as
previously described (Szafran et al., 2008).
Support Vector Machine Classification
For each experiment, a validation data set was created consisting of 16 wells
for the following control treatments: vehicle (ethanol), agonist (10 nM DHT),
a negative ligand control (10 mM OHF), and antagonist (10 mM OFH/1 nM
DHT). After the image analysis and feature extraction steps described earlier,
single-cell-level measurements were used to train a classifier on the control
data set to distinguish between the control treatments. Before training,
1,000 single-cell samples were randomly sampled (without replacement)
from each control treatment to ensure classeswere equally sized in the training
process. Next, linearly dependent features were removed. All other features
were scaled to a range of [1,1]. Feature selection was performed on the
training data using stepwise discriminant analysis (SDA), which defines a list
of the most discriminative feature for classification (Jennrich, 1977). Finally,
we used the SDA-selected features to train a support vector machine (SVM)
classifier with a radial-basis-function kernel (Cortes and Vapnik, 1995). Tenfold
cross-validation on the training data was used with a grid search to optimize
the parameters C (slack penalty) and g (kernel parameter).
For validation, we randomly sampled 10 different sets upon which we
trained a classifier, and for each corresponding subtraining set, we tested its
classifier on the remaining control samples. Resulting classification labels
were used to calculate precision and recall scores for each classifier, and
these accuracy metrics were averaged across the panel of classifiers to
produce a performance measure for the classification approach. The super-
vised learning approach was implemented in Python 2.6 and utilizes LIBSVM
2.9 (http://www.csie.ntu.edu.tw/cjlin/libsvm/).
Statistical Analyses
Data presented were acquired from a minimum of two (quantitative real-time
PCR) or three (HCA) independent experiments performed on multiple days,
unless otherwise indicated. ANOVA was first used to compare the effects of2 Elsevier Ltd All rights reserved
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Androgen Receptor Regulation in Human Adipocytestime or ligand treatment. If significant differences were identified, then data
were compared with Tukey’s honestly significant difference post hoc tests.
All tests were carried out at the 95% confidence interval using JMP-IN 7
(SAS, Cary, NC, USA).
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